Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$97.3 million.

  • Agios Pharmaceuticals' Free Cash Flow rose 2743.6% to -$97.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$377.3 million, marking a year-over-year increase of 363.53%. This contributed to the annual value of -$377.3 million for FY2025, which is 363.53% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Free Cash Flow stood at -$97.3 million for Q4 2025, which was up 2743.6% from -$89.7 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Free Cash Flow ranged from a high of -$62.0 million in Q3 2023 and a low of -$134.1 million during Q4 2024
  • Its 5-year average for Free Cash Flow is -$89.7 million, with a median of -$86.9 million in 2021.
  • In the last 5 years, Agios Pharmaceuticals' Free Cash Flow skyrocketed by 3521.09% in 2022 and then plummeted by 8444.76% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Free Cash Flow stood at -$88.6 million in 2021, then rose by 25.19% to -$66.3 million in 2022, then dropped by 9.73% to -$72.7 million in 2023, then crashed by 84.45% to -$134.1 million in 2024, then increased by 27.44% to -$97.3 million in 2025.
  • Its last three reported values are -$97.3 million in Q4 2025, -$89.7 million for Q3 2025, and -$78.0 million during Q2 2025.